We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

169 hedge funds and large institutions have $655M invested in Ariad Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 169169 (0)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

17% less capital invested

Capital invested by funds: $790M → $655M (-$135M)

23% less call options, than puts

Call options by funds: $20.5M | Put options by funds: $26.5M

Holders
169
Holders Change
Holders Change %
0%
% of All Funds
4.9%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
25
Increased
61
Reduced
44
Closed
24
Calls
$20.5M
Puts
$26.5M
Net Calls
-$6.01M
Net Calls Change
-$11M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$69.4M +$4.96M +850,000 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$56.4M -$1.29M -220,220 -2%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$52M -$22M -3,759,109 -28%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$50.4M +$7.95M +1,362,007 +17%
BFA
5
BlackRock Fund Advisors
California
$39.3M +$4.89M +837,137 +13%
CCM
6
Camber Capital Management
Massachusetts
$32.4M +$5.84M +1,000,000 +20%
State Street
7
State Street
Massachusetts
$31.6M +$473K +81,039 +1%
BIT
8
BlackRock Institutional Trust
California
$26M -$80.2K -13,725 -0.3%
PC
9
PointState Capital
New York
$20.3M +$10.5M +1,800,000 +92%
HM
10
HealthCor Management
New York
$12.8M +$5.93M +1,015,000 +75%
CCI
11
Columbus Circle Investors
$12.6M +$13.6M +2,326,416 New
PAI
12
Palo Alto Investors
California
$12.1M -$256K -43,886 -2%
Norges Bank
13
Norges Bank
Norway
$11.5M -$12.4M -2,123,115 -50%
Northern Trust
14
Northern Trust
Illinois
$11.3M +$6.45M +1,104,388 +112%
DFO
15
Duquesne Family Office
New York
$8.88M +$9.61M +1,645,000 New
Ameriprise
16
Ameriprise
Minnesota
$8.81M +$43.2K +7,398 +0.5%
O
17
OppenheimerFunds
New York
$8.75M +$9.46M +1,620,560 New
Millennium Management
18
Millennium Management
New York
$8.44M +$8.33M +1,426,429 +1,043%
BNP Paribas Asset Management
19
BNP Paribas Asset Management
France
$8.33M +$5.39M +922,311 +149%
OM
20
Opaleye Management
Massachusetts
$8.1M -$934K -160,000 -10%
JP Morgan Chase
21
JP Morgan Chase
New York
$8.07M +$6.42M +1,100,056 +279%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$8.03M -$1.81M -309,662 -17%
AQR Capital Management
23
AQR Capital Management
Connecticut
$7.8M -$14.2M -2,439,116 -63%
Renaissance Technologies
24
Renaissance Technologies
New York
$6.76M -$18.4M -3,147,300 -72%
GAI
25
General American Investors
New York
$6.48M

ARIA Hedge Fund Activity: Q3 2014 in Review

169 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2014, worth a combined $655M — down 17% from $790M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ARIA positions and 24 closed out — a net gain of 1 holder — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Columbus Circle Investors, opening a new position worth an estimated $13.6M. The largest seller was Franklin Resources, exiting entirely with an estimated $32.1M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $655M of Ariad Pharmaceuticals Inc stock for Q3 2014, down 17% quarter-over-quarter.
  • 25 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2014 and 24 closed out, a net change of +1 holder.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2014 was Columbus Circle Investors, an estimated $13.6M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2014 was Franklin Resources, an estimated $32.1M sold.

Based on aggregated 13F filings for Q3 2014.